Public Policy

February, 2022

Abstract

Vaccination policies have shifted dramatically during COVID-19 with the rapid emergence of population-wide vaccine mandates, domestic vaccine passports, and differential restrictions based on vaccination status. These policies have prompted ethical, scientific, practical, and political controversy; however, there has been limited evaluation of their potential unintended consequences. Here, we outline a comprehensive set of hypotheses for why these policies may be counter-productive and harmful.

Our framework considers four domains:

January, 2022

Abstract

DSA ADS Course - 2022

COVID19, Public Policy, Health Policy, mRNA Vaccines, Vaccines, Clinical Trial Design, Evidence Hierarchy

This is a FOIA document of the first 2.5 months after the vaccine roll-out. Discuss clinical trial design and hierarchy of evidence in context of mRNA vaccines.

5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

DSA ADS Course - 2022

COVID19, Public Policy, Health Policy, mRNA Vaccines, Vaccines, Clinical Trial Design, Evidence Hierarchy

Discuss clinical trial design and hierarchy of evidence in context of mRNA vaccines.

The Pfizer Inoculations Do More Harm Than Good - December, 2021

See also video: https://rumble.com/vqx3kb-the-pfizer-inoculations-do-more-harm-than-good.html

April, 2020

Abstract

December, 2021

Highlights

• Describes a novel causal Bayesian network approach for systematic product risk assessment.

• The approach resolves some limitations with current commonly used product risk assessment methods.

• The approach complements product risk assessment methods like RAPEX.

• The approach can produce quantified, auditable product risk assessment with limited or no testing data.

Abstract